Regenxbio (NASDAQ:RGNX) is a biotechnology company focused on the development, commercialization, and licensing of its proprietary NAV technology platform for gene therapy. Its operations are dedicated to discovering and developing therapeutics to improve the lives of patients suffering from serious diseases, including genetic disorders, metabolic diseases, and retinal diseases. Through its versatile NAV technology platform, Regenxbio is advancing a diverse pipeline of gene therapy candidates with the aim of addressing unmet medical needs. The company's objectives center around leveraging its leading technology platform to create transformative gene therapies that can offer long-lasting effects and improve patient health outcomes. In pursuit of these goals, Regenxbio actively engages in research and development, clinical trials, and strategic collaborations to expand its portfolio and enhance the potential of gene therapy applications.